References
- Genazzani AD. Expert’s opinion: integrative treatment with inositols and lipoic acid for insulin resistance in PCOS. Gynecol Reprod Endocrinol Metab. 2020;1:146–157.
- Roberts CK, Hevener AL, Barnard RJ. Metabolic syndrome and insulin resistance: underlying causes and modification by exercise training. Compr Physiol. 2013;3(1):1–58.
- Yildiz BO, Bozdag G, Yapici Z, et al. Prevalence, phenotype and cardiometabolic risk of polycystic ovary syndrome under different diagnostic criteria. Hum Reprod. 2012;27(10):3067–3073.
- Genazzani AD, Ricchieri F, Lanzoni C. Use of metformin in the treatment of polycystic ovary syndrome. Womens Health (Lond). 2010;6(4):577–593.
- Sortino MA, Salomone S, Carruba MO, et al. Polycystic Ovary Syndrome: insights into the therapeutic approach with inositols. Front Pharmacol. 2017;8:341.
- El Hayek S, Bitar L, Hamdar LH, Mirza FG, et al. Poly cystic ovarian syndrome: an updated overview. Front. Physiol. 2016;7:124.
- Genazzani AD. Inositol as putative integrative treatment for PCOS. Reprod Biomed Online. 2016;33(6):770–780.
- Unfer V, Proietti S, Gullo G, et al. Polycystic ovary syndrome: features, diagnostic criteria and treatments. Endocrinol Metab Syndr. 2014;3:3.
- Thomas RM, Nechamen CA, Mazurkiewicz JE, et al. The adapter protein APPL1 links FSH receptor to inositol 1,4,5-trisphosphate production and is implicated in intracellular Ca(2+) mobilization. Endocrinology. 2011;152(4):1691–1701.
- Larner J, Brautigan DL, Thorner MO. D-chiro-inositol glycans in insulin signaling and insulin resistance. Mol Med. 2010;16(11–12):543–552.
- Baillargeon JP, Diamanti-Kandarakis E, Ostlund RE, Jr, et al. Altered D-chiro-inositol urinary clearance in women with polycystic ovary syndrome. Diabetes Care. 2006;29(2):300–305.
- Baillargeon JP, Nestler JE, Ostlund RE, et al. Greek hyperinsulinemic women, with or without polycystic ovary syndrome, display altered inositols metabolism. Hum Reprod. 2008;23(6):1439–1446.
- Genazzani AD, Prati A, Marchini F, et al. Differential insulin response to oral glucose tolerance test (OGTT) in overweight/obese polycystic ovary syndrome patients undergoing to myo-inositol (MYO), alpha lipoic acid (ALA), or combination of both. Gynecol Endocrinol. 2019;35(12):1088–1093.
- Genazzani AD, Santagni S, Rattighieri E, et al. Modulatory role of D-chiro-inositol (DCI) on LH and insulin secretion in obese PCOS patients. Gynecol Endocrinol. 2014;30(6):438–443.
- de Melo AS, Vilan Dias S, de Carvalho Cavalli R, et al. Pathogenesis of polycystic ovary syndrome: multifactorial assessment from the foetal stage to menopause. Reproduction. 2015;150(1):R11–R24.
- Roseff S, Montenegro M. Inositol treatment for PCOS should be science-based and not arbitrary. Int J Endocrinol. 2020;2020:6461254. eCollection 2020.
- Garzon S, Lagana AS, Monastra G. Risk of reduced intestinal absorption of myo-inositol caused by D-chiroinositol or by glucose transporter inhibitors. Expert Opin Drug Metab Toxicol. 2019;15(9):697–703.